低分子肝素对持续性房颤患者凝血、纤溶、和抗凝指标的影响  

Effect of low molecular weight heparin on hemostasis,fibrinolysis and anticoagulation system in treatment of persistent atrial fibrillation

作　　者：刘军委[1] 

机构地区：[1]河南省商丘市第一人民医院心内科,476000

出　　处：《中国实用医药》2008年第25期42-43,共2页China Practical Medicine

摘　　要：目的观察在持续性房颤患者的高凝状态时应用低分子肝素的疗效及安全性。方法持续性房颤患者56例,年龄(57±3.7)岁,房颤病史(3.8±1.7)年。给予低分子肝素(克塞)60mg,2次/d,皮下注射,两周1个疗程。测定1周后和两周后的凝血指标:血浆凝血酶原时间(PT)、活化部分凝血酶时间(aPTT)、血浆D-二聚体、血浆纤溶酶原激活物抑制物(PAI)、血浆组织型纤溶酶原激活物(tPA)、抗Xa因子活性、抗凝血酶Ⅲ(AT-Ⅲ)活性。结果用药1周后PT、aPTT升高,而两周后恢复正常,tPA、抗Xa因子活性增高,血浆D-二聚体减低明显(P≤0.05)。结论低分子肝素(克塞)60mg,2次/d,皮下注射,两周1个疗程治疗持续性房颤患者疗效确切,安全方便。Objective To observed the effective and salty of low molecular weight heparin,in the treatment of persistent atrial fibrillation： Methods 56 patienta aged 57 ± 3.7years with persistent atrial fibrillation were treated with low molecular weight heparin subcutaneous in injection once every 12 hours for 14 days. The plasma PT,aVIT AXa D-dimer tPA PAl and AT-Ⅲ were detected before the treatment and 4 hours after one week the last single subcutaneous in injection and 4 hours after two weeks. Results Results showed thatPT, atilt prolonged slightly, one week P 〈 0. 05 twoweeks P 〉 0. 05. AXa, tPA levels increased （P 〈 0. 05 ）and D-dimer activity decteased （P 〈 0. 05 ）. after two weeks. Conclusion Low molecular weight heparin in the treatment of persistent atrial fibrillation is effective and safty.

关 键 词：持续性房颤 低分子肝素 临床分析 疗效 

分 类 号：R541.75[医药卫生—心血管疾病] R541.4[医药卫生—内科学]